UY39172A - Análogos de nucleósido bi- y monocíclicos para el tratamiento de la hepatitis e - Google Patents

Análogos de nucleósido bi- y monocíclicos para el tratamiento de la hepatitis e

Info

Publication number
UY39172A
UY39172A UY0001039172A UY39172A UY39172A UY 39172 A UY39172 A UY 39172A UY 0001039172 A UY0001039172 A UY 0001039172A UY 39172 A UY39172 A UY 39172A UY 39172 A UY39172 A UY 39172A
Authority
UY
Uruguay
Prior art keywords
hepatitis
treatment
nucleoside analogues
monocyclic nucleoside
monocyclic
Prior art date
Application number
UY0001039172A
Other languages
English (en)
Spanish (es)
Inventor
Frederik Pauwels
Yannick Debing
Tim Hugo Maria Jonckers
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of UY39172A publication Critical patent/UY39172A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
UY0001039172A 2020-04-14 2021-04-13 Análogos de nucleósido bi- y monocíclicos para el tratamiento de la hepatitis e UY39172A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20169480 2020-04-14

Publications (1)

Publication Number Publication Date
UY39172A true UY39172A (es) 2021-10-29

Family

ID=70289599

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039172A UY39172A (es) 2020-04-14 2021-04-13 Análogos de nucleósido bi- y monocíclicos para el tratamiento de la hepatitis e

Country Status (15)

Country Link
EP (1) EP4135715B1 (cg-RX-API-DMAC7.html)
JP (2) JP2023522615A (cg-RX-API-DMAC7.html)
KR (1) KR20230002592A (cg-RX-API-DMAC7.html)
CN (1) CN115515603A (cg-RX-API-DMAC7.html)
AR (1) AR121836A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021255809B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022020825A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174790A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002804A1 (cg-RX-API-DMAC7.html)
ES (1) ES2982564T3 (cg-RX-API-DMAC7.html)
MX (1) MX2022012904A (cg-RX-API-DMAC7.html)
PE (1) PE20230386A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552679A1 (cg-RX-API-DMAC7.html)
UY (1) UY39172A (cg-RX-API-DMAC7.html)
WO (1) WO2021209419A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024086592A2 (en) * 2022-10-17 2024-04-25 Emory Unversity 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2025014360A1 (en) * 2023-07-07 2025-01-16 Erasmus University Medical Center Rotterdam Guanosine nucleotide analogs for use in preventing and/or treating hepatitis e virus infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2952714T3 (es) * 2013-06-26 2023-11-03 Janssen Pharmaceuticals Inc Nucleósidos sustituidos, nucleótidos y análogos de los mismos
US9603864B2 (en) * 2014-06-24 2017-03-28 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
SG11201610597QA (en) * 2014-06-24 2017-01-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2017210438A1 (en) * 2016-06-03 2017-12-07 Gilead Pharmasset Llc Methods of treating hepatitis e viral infection

Also Published As

Publication number Publication date
CA3174790A1 (en) 2021-10-21
US20230310481A1 (en) 2023-10-05
EP4135715A1 (en) 2023-02-22
CL2022002804A1 (es) 2023-03-31
AU2021255809B2 (en) 2026-08-06
CN115515603A (zh) 2022-12-23
PH12022552679A1 (en) 2024-04-22
BR112022020825A2 (pt) 2022-11-29
EP4135715B1 (en) 2024-05-08
ES2982564T3 (es) 2024-10-16
MX2022012904A (es) 2023-01-24
AU2021255809A1 (en) 2022-12-15
PE20230386A1 (es) 2023-03-06
EP4135715C0 (en) 2024-05-08
WO2021209419A1 (en) 2021-10-21
AR121836A1 (es) 2022-07-13
KR20230002592A (ko) 2023-01-05
JP2023522615A (ja) 2023-05-31
JP2026120528A (ja) 2026-07-22

Similar Documents

Publication Publication Date Title
DOP2022000293A (es) Análogos de nucleósido de 1’-ciano y usos de los mismos
CR20220236A (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune
MX2022000453A (es) Compuestos útiles para tratar infecciones por virus de influenza.
CL2020001146A1 (es) Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb).
UY38434A (es) Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv)
ECSP20029558A (es) Nuevas indol-2-carboxamidas sustituidas con amino-tiazol, de alta actividad, activas contra el virus de la hepatitis b (vhb)
UY39027A (es) Uso de favipiravir en el tratamiento de la infección por coronavirus
CO2020005420A2 (es) Compuestos antibacterianos
ECSP18061667A (es) Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza
CU24519B1 (es) Derivados de aminotiazol útiles como agentes antivíricos
ECSP21079317A (es) Nuevas indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
ECSP21031085A (es) Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
CO2024006727A2 (es) Compuestos y composiciones macrocíclicos, y métodos para preparar y utilizar los mismos
CL2024003512A1 (es) Compuestos antivirales derivados de indolinilo.
CL2024000560A1 (es) Inhibidores de indolina de kif18a
DOP2018000183A (es) Compuesto útil para el tratamiento y la profilaxis de vih y sida y sus usos
MX2022009176A (es) Metodo y composiciones para el tratamiento de infeccion por coronavirus.
CO2021011023A2 (es) Compuesto heterocíclico, composición farmacéutica que lo comprende, método para su preparación, y uso de estos
BR112023001129A2 (pt) Pró-fármacos antivirais, formulações farmacêuticas e métodos
MX2023008004A (es) Derivado de adenosina y composicion farmaceutica que lo comprende.
CL2022002804A1 (es) Análogos del nucleósido bicíclico y monocíclico para el tratamiento de la hepatitis e.
CO2025018006A2 (es) Formas sólidas de un inhibidor macrocíclico de farnesiltransferasa y formulaciones de estos, y métodos de preparación y uso del compuesto macrocíclico y sus formas sólidas
BR112023016958A2 (pt) Compostos para uso no tratamento de uma infecção por vírus envelopado
UY37166A (es) Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano
BR112022020810A2 (pt) Análogos de nucleosídeos espirocíclicos para o tratamento de hepatite e